logo
logo

Exscientia Announces Closing Of $510.4 Million Aggregate Financing, Consisting Of $350.4 Million Upsized Initial Public Offering With Full Exercise Of Underwriters’ Option To Purchase Additional Adss And $160.0 Million Concurrent Private Placement

Exscientia Announces Closing Of $510.4 Million Aggregate Financing, Consisting Of $350.4 Million Upsized Initial Public Offering With Full Exercise Of Underwriters’ Option To Purchase Additional Adss And $160.0 Million Concurrent Private Placement

10/05/21, 8:01 PM
Location
https://purecatamphetamine.github.io/country-flag-icons/3x2/US.svgoxford
Money raised
$510 million
Exscientia plc (Nasdaq: EXAI), an AI-driven pharmatech company committed to discovering, designing and developing the best possible drugs in the fastest and most effective manner, today announced the closing of its previously-announced upsized initial public offering in the United States of 15,927,500 American Depositary Shares (“ADSs”) representing 15,927,500 ordinary shares, including 2,077,500 ADSs sold pursuant to the full exercise of the underwriters’ previously granted option to purchase additional ADSs. All ADSs sold in the offering were offered by Exscientia at a public offering price of $22.00 per ADS. The total gross proceeds to Exscientia from the offering were approximately $350.4 million, prior to deducting underwriting discounts and commissions and estimated offering expenses payable by Exscientia. The offering was upsized from the number of shares offered at launch and priced at the top of the price range indicated at launch.

Company Info

Company
Exscientia
Location
oxford, mississippi, united states
Additional Info
Exscientia is an AI-driven pharmatech company committed to discovering, designing and developing the best possible drugs in the fastest and most effective manner. Exscientia developed the first-ever functional precision oncology platform to successfully guide treatment selection and improve patient outcomes in a prospective interventional clinical study, as well as to progress AI-designed small molecules into the clinical setting. Our pipeline demonstrates our ability to rapidly translate scientific concepts into precision-designed therapeutic candidates, with more than 25 projects advancing, including the first three AI-designed drug candidates to enter Phase 1 clinical trials.

Related People